Dublin, March 13, 2025 (GLOBE NEWSWIRE) — The “Kidney Cancer Drugs – Global Strategic Business Report” has been added to ResearchAndMarkets.com’s offering.
The global market for Kidney Cancer Drugs was valued at US$6.1 billion in 2024 and is projected to reach US$8.1 billion by 2030, growing at a CAGR of 4.8% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
The market for kidney cancer drugs is driven by multiple factors that contribute to its growth and evolution. Technological advances in drug development, spurred by molecular biology and cancer genomics, allow for more targeted and effective therapies with fewer side effects, fostering a shift towards precision medicine tailored to specific genetic profiles of patients and tumors.
Regulatory support, including accelerated approvals for breakthrough therapies and incentives for orphan drugs, aids in the rapid introduction of innovative treatments. The integration of artificial intelligence in drug development streamlines the discovery and testing of new drugs, reducing time and cost. Collaborations among pharmaceutical companies, biotechnology firms, and academic institutions enhance the development pipeline. Moreover, there is an increasing preference for outpatient cancer therapies that offer convenience and reduce hospital visits.
Patient advocacy and enhanced awareness lead to earlier diagnosis and treatment, while economic growth and better insurance coverage support the adoption of new, often costly, treatments. Global health trends, including rising obesity and hypertension rates, further drive the demand for effective kidney cancer treatments, shaping a dynamic market poised for continued innovation and growth.
Report Scope
The report analyzes the Kidney Cancer Drugs market, presented in terms of market value (USD). The analysis covers the key segments and geographic regions outlined below.
Segments
Therapeutic Class (Targeted Therapy, Immunotherapy); Pharmacologic Class (Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies, Cytokine Immunotherapy (IL-2)).
Geographic Regions/Countries
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Targeted Therapy segment, which is expected to reach US$5.6 Billion by 2030 with a CAGR of a 5.1%. The Immunotherapy segment is also set to grow at 4.2% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $1.6 Billion in 2024, and China, forecasted to grow at an impressive 8.1% CAGR to reach $1.7 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Bayer AG, Bristol-Myers Squibb Company, Eisai Co., Ltd., Exelixis, Inc., Novartis International AG and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Key Questions Answered:
- How is the Global Kidney Cancer Drugs Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Some of the 12 companies featured in this Kidney Cancer Drugs market report include:
- Bayer AG
- Bristol-Myers Squibb Company
- Eisai Co. Ltd.
- Exelixis Inc.
- Novartis International AG
- Pfizer Inc.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 148 |
| Forecast Period | 2024-2030 |
| Estimated Market Value (USD) in 2024 | $6.1 Billion |
| Forecasted Market Value (USD) by 2030 | $8.1 Billion |
| Compound Annual Growth Rate | 4.8% |
| Regions Covered | Global |
MARKET OVERVIEW
- Influencer Market Insights
- Kidney Cancer Drugs – Global Key Competitors Percentage Market Share in 2025 (E)
- Competitive Market Presence – Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
- Global Economic Update
MARKET TRENDS & DRIVERS
- Rising Incidence of Kidney Cancer Propels Demand for Effective Treatment Options
- Increasing Awareness and Early Diagnosis of Kidney Cancer Accelerates Market Penetration
- Advances in Targeted Therapy and Immunotherapy Strengthen Business Case for Innovative Kidney Cancer Drugs
- Focus on Personalized Medicine Drives Adoption of Precision Kidney Cancer Drugs
- Growing Geriatric Population and Associated Cancer Risk Spurt Growth in Kidney Cancer Drugs Market
- Introduction of Combination Therapies Throws the Spotlight on Enhanced Treatment Efficacy
- Advances in Biomarker Identification Propel Development of Targeted Kidney Cancer Drugs
- Focus on Minimizing Side Effects and Improving Quality of Life Sustains Demand for Innovative Drugs
- Growing Adoption of Oral Chemotherapy Drugs Expands Treatment Options for Patients
- Advances in Molecular Diagnostics Propel Growth in Precision Medicine for Kidney Cancer
- Increasing Number of Clinical Trials and Pipeline Drugs Enhance Market Potential
- Expansion of Telemedicine and Remote Patient Monitoring Drives Market Adoption
- Focus on Patient-Centric Care Models Generates Demand for Personalized Kidney Cancer Treatments
- Advances in Drug Delivery Systems Propel Development of Novel Kidney Cancer Therapies
- Rising Prevalence of Lifestyle-Related Risk Factors Expands Addressable Market Opportunity
- Development of Biosimilars and Generics Throws the Spotlight on Affordable Treatment Options
- Increasing Focus on Integrative and Complementary Therapies Drives Demand for Holistic Treatment Approaches
For more information about this report visit https://www.researchandmarkets.com/r/osy2tt
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Kidney Cancer Drugs Market
